Overview

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Patients Undergoing Open-chest Cardiac Surgery (NOVA)

Status:
Recruiting

Trial end date:
2023-02-27

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of ganglionic plexi, to prevent Post-Operative Atrial Fibrillation (POAF) in patients undergoing open-chest cardiac surgery.

Phase:

Phase 2

Details

Lead Sponsor:

Allergan

Treatments:

abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A
onabotulinumtoxinA